Tvardi Therapeutics released FY2024 earnings on May 30, 2025 (EST) with actual revenue of USD 0 and EPS of USD -11.42

Brief Summary

According to its fiscal year 2024 annual report released on May 30, 2025 (US Eastern Time), Tvardi Therapeutics, a US-listed company, reported zero revenue, a net loss of $29.397 million, and an earnings per share (EPS) of -$11.42.

Impact of The News

Analysis of Tvardi Therapeutics’ FY2024 Financial Report